Shares of Eli Lilly (NYSE: LLY), known for its weight loss drugs Mounjaro and Zepbound, increased by 2.5% by 1:55 p.m. ET on Monday, following a positive recommendation from Bernstein, which labeled the stock as a buy. This uptick reflects investors’ optimism based on favorable news from Wall Street.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
